0001628280-23-040702.txt : 20231205 0001628280-23-040702.hdr.sgml : 20231205 20231205085128 ACCESSION NUMBER: 0001628280-23-040702 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20231205 ITEM INFORMATION: Other Events FILED AS OF DATE: 20231205 DATE AS OF CHANGE: 20231205 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Aquestive Therapeutics, Inc. CENTRAL INDEX KEY: 0001398733 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 208623253 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38599 FILM NUMBER: 231465314 BUSINESS ADDRESS: STREET 1: 30 TECHNOLOGY DRIVE CITY: WARREN STATE: NJ ZIP: 07059 BUSINESS PHONE: 908-941-1900 MAIL ADDRESS: STREET 1: 30 TECHNOLOGY DRIVE CITY: WARREN STATE: NJ ZIP: 07059 FORMER COMPANY: FORMER CONFORMED NAME: MonoSol Rx, Inc. DATE OF NAME CHANGE: 20070507 8-K 1 aqst-20231205.htm 8-K aqst-20231205
0001398733false00013987332023-12-052023-12-05

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): December 5, 2023
Aquestive Therapeutics, Inc.
(Exact name of Registrant as specified in its charter)
Delaware001-3859982-3827296
(State or Other Jurisdiction of Incorporation or Organization)(Commission File Number)(I.R.S. Employer Identification No.)

30 Technology Drive
Warren, NJ 07059
(908) 941-1900
(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant’s Principal Executive Offices)

Not Applicable
(Former name or former address, if changed since last report)
________________________________________________________________________________________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading Symbol(s)Name of each exchange on which
registered
Common Stock, par value $0.001 per shareAQSTNasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


Item 8.01
Other Events
On December 5, 2023, Aquestive Therapeutics, Inc. (the “Company”) issued a press release announcing that the first patient has been dosed in its initial Phase 3 pivotal Pharmacokinetic (PK) clinical study of Anaphylm™ (epinephrine) Sublingual Film. Anaphylm is the Company’s orally administered epinephrine prodrug product candidate under development for the treatment of severe life-threatening allergic reactions, including anaphylaxis.

A copy of the Company’s press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated into this Item 8.01 by reference.

Cautionary Note Regarding Forward-Looking Statements

Certain statements in this Current Report on Form 8-K include “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believe,” “anticipate,” “plan,” “expect,” “estimate,” “intend,” “may,” “will,” or the negative of those terms, and similar expressions, are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the advancement and related timing of our product candidate Anaphylm™ (epinephrine) Sublingual Film through clinical development and approval by the FDA, regarding the potential benefits Anaphylm could bring to patients, and other statements that are not historical facts. These forward-looking statements are subject to the uncertain impact of the COVID-19 global pandemic on the Company’s business including with respect to its clinical trials including site initiation, enrollment and timing and adequacy of clinical trials; on regulatory submissions and regulatory reviews and approval of Anaphylm and Libervant, pharmaceutical ingredient and other raw materials supply chain, manufacture, and distribution; and ongoing availability of an appropriate labor force and skilled professionals.

These forward-looking statements are based on the Company’s current expectations and beliefs and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Such risks and uncertainties include, but are not limited to, risks associated with the Company’s development work, including any delays or changes to the timing, cost and success of its product development activities and clinical trials for Anaphylm and our other product candidates; risk of the Company’s ability to generate sufficient data in its PK/PD comparability submission for FDA approval of Anaphylm; risk of the Company’s ability to address the FDA’s comments on the Company’s pivotal PK study protocol and other concerns identified in the FDA End-of-Phase 2 meeting for Anaphylm, including the risk that the FDA may require additional clinical studies for approval of Anaphylm; risk of delays in or the failure to receive FDA approval of Anaphylm; risks associated with the Company’s development work, including any delays or changes to the timing, cost and success of the Company’s product development activities; risk of the success of any competing products; risk inherent in commercializing a new product (including technology risks, financial risks, market risks and implementation risks, and regulatory limitations); risk of the rate and degree of market acceptance of our product candidates and our licensed products in the U.S. and abroad; risk of insufficient capital and cash resources, including insufficient access to available debt and equity financing and revenues from operations, to satisfy all of the Company’s short-term and longer term liquidity and cash requirements and other cash needs, at the times and in the amounts needed, including to fund future clinical development activities for our other product candidates; risk of the size and growth of our product markets; risks of compliance with all FDA and other governmental and customer requirements for our manufacturing facilities; risks associated with intellectual property rights and infringement claims relating to the Company's products; risk of unexpected patent developments; uncertainties related to general economic, political (including acts of war and terrorism), business, industry, regulatory, financial and market conditions and other unusual items; and other risks and uncertainties affecting the Company described in the “Risk Factors” section and in other sections included in the Company’s 2022 Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K filed with the U.S. Securities and Exchange Commission. Given those uncertainties, you should not place undue reliance on these forward-looking statements, which speak only as of the date made. All subsequent forward-looking statements attributable to the Company or any person acting on its behalf are expressly qualified in their entirety by this cautionary statement. The Company assumes no obligation to update forward-looking statements or outlook or guidance after the date of this Current Report on Form 8-K whether as a result of new information, future events or otherwise, except as may be required by applicable law.



Item 9.01
Financial Statements and Exhibits




SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: December 5, 2023
Aquestive Therapeutics, Inc.
By:/s/ A. Ernest Toth, Jr
Name: A. Ernest Toth, Jr.
Title: Chief Financial Officer
(Principal Financial Officer)


    

 EX-99.1 2 aqst_firstpatientdosedinpa.htm EX-99.1 Document
image_0.jpg
Aquestive Therapeutics Doses First Patient in Phase 3 Pivotal Clinical Study Evaluating Pharmacokinetics and Pharmacodynamics of Anaphylm™ (epinephrine) Sublingual Film

•Commences initial Phase 3 study with first orally delivered epinephrine prodrug candidate
•Reaffirms topline data anticipated in first quarter 2024

WARREN, N.J., December 5, 2023 -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that the first patient has been dosed in its initial Phase 3 pivotal Pharmacokinetic (PK) clinical study of Anaphylm™ (epinephrine) Sublingual Film. Anaphylm is the Company’s orally administered epinephrine prodrug product candidate under development for the treatment of severe life-threatening allergic reactions, including anaphylaxis.

The two-part, Phase 3, single-center, open-label, randomized study is designed to compare the PK and pharmacodynamics (PD) of single and repeat doses of Anaphylm versus single and repeat doses of the epinephrine IM injection and epinephrine autoinjectors (EpiPen® and Auvi-Q®) in healthy adult subjects. The primary objective is to compare the PK of epinephrine following the single administration of Anaphylm to single administration of epinephrine IM injection in healthy adult subjects. The secondary objectives include evaluating PK sustainability following repeat administration and evaluating the safety and tolerability following single and repeat administrations versus epinephrine IM injection and epinephrine autoinjectors.

“With the dosing of our first patient, we are officially one step closer to reaching our goal of filing our Anaphylm New Drug Application with the FDA in 2024,” said Daniel Barber, Chief Executive Officer of Aquestive. “Anaphylm continues to be the first and only non-invasive, orally delivered epinephrine product candidate to demonstrate clinical results comparable to autoinjectors for the emergency treatment of severe allergic reactions, including anaphylaxis. We remain focused on continuing to demonstrate the PK comparability of Anaphylm to existing autoinjectors. We remain excited to address the significant unmet need for an orally delivered, convenient and effective product candidate.”

Part A of the two-part Phase 3 is designed as a three-period, three-treatment, six sequence, comparative PK study and is expected to enroll up to 36 subjects. Part A will assess both the PK performance and sustainability of Anaphylm 12mg with the bracketed comparison of an epinephrine autoinjector (EpiPen) and epinephrine manual IM injection. Part B is designed as a four-period, four-treatment, four-sequence, comparative PK study and is expected to enroll up to 64 subjects, inclusive of those who participated in Part A. Part B will assess the PK of a single dose of Anaphylm 12mg with the bracketed comparison of two autoinjectors (EpiPen and Auvi-Q) and the manual IM injection.

About Anaphylm™
Anaphylm is a polymer matrix-based epinephrine prodrug candidate product. The product is similar in size to a postage stamp, weighs less than an ounce, and begins to dissolve on contact. No water or swallowing is required for administration. The packaging for Anaphylm is thinner and smaller than an average credit card, can be carried in a pocket, and is designed to withstand weather excursions such as exposure to rain and/or sunlight. The tradename for AQST-109 “Anaphylm” has been conditionally approved by the FDA. Final approval of the Anaphylm proprietary name is conditioned on FDA approval of the product candidate.

About Aquestive Therapeutics
Aquestive is pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies. We are developing orally administered products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. Aquestive has five commercialized products marketed by its licensees in the U.S. and around the world, and is the exclusive manufacturer of these licensed products. The Company also collaborates with pharmaceutical companies to bring new molecules to market using proprietary, best-in-class technologies, like PharmFilm®, and has proven drug development and commercialization capabilities. Aquestive is advancing a late-stage proprietary product pipeline focused on treating diseases of the central nervous system and an earlier stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. For more information, visit Aquestive.com and follow us on LinkedIn.

image_0.jpg

Forward-Looking Statement
Certain statements in this press release include “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believe,” “anticipate,” “plan,” “expect,” “estimate,” “intend,” “may,” “will,” or the negative of those terms, and similar expressions, are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the advancement and related timing of our product candidate Anaphylm™ (epinephrine) Sublingual Film through clinical development and approval by the FDA, regarding the potential benefits Anaphylm could bring to patients, and other statements that are not historical facts. These forward-looking statements are subject to the uncertain impact of the COVID-19 global pandemic on the Company’s business including with respect to its clinical trials including site initiation, enrollment and timing and adequacy of clinical trials; on regulatory submissions and regulatory reviews and approval of Anaphylm and Libervant, pharmaceutical ingredient and other raw materials supply chain, manufacture, and distribution; and ongoing availability of an appropriate labor force and skilled professionals.

These forward-looking statements are based on the Company’s current expectations and beliefs and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Such risks and uncertainties include, but are not limited to, risks associated with the Company’s development work, including any delays or changes to the timing, cost and success of its product development activities and clinical trials for Anaphylm and our other product candidates; risk of the Company’s ability to generate sufficient data in its PK/PD comparability submission for FDA approval of Anaphylm; risk of the Company’s ability to address the FDA’s comments on the Company’s pivotal PK study protocol and other concerns identified in the FDA End-of-Phase 2 meeting for Anaphylm, including the risk that the FDA may require additional clinical studies for approval of Anaphylm; risk of delays in or the failure to receive FDA approval of Anaphylm; risks associated with the Company’s development work, including any delays or changes to the timing, cost and success of the Company’s product development activities; risk of the success of any competing products; risk inherent in commercializing a new product (including technology risks, financial risks, market risks and implementation risks, and regulatory limitations); risk of the rate and degree of market acceptance of our product candidates and our licensed products in the U.S. and abroad; risk of insufficient capital and cash resources, including insufficient access to available debt and equity financing and revenues from operations, to satisfy all of the Company’s short-term and longer term liquidity and cash requirements and other cash needs, at the times and in the amounts needed, including to fund future clinical development activities for our other product candidates; risk of the size and growth of our product markets; risks of compliance with all FDA and other governmental and customer requirements for our manufacturing facilities; risks associated with intellectual property rights and infringement claims relating to the Company's products; risk of unexpected patent developments; uncertainties related to general economic, political (including acts of war and terrorism), business, industry, regulatory, financial and market conditions and other unusual items; and other risks and uncertainties affecting the Company described in the “Risk Factors” section and in other sections included in the Company’s 2022 Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K filed with the U.S. Securities and Exchange Commission. Given those uncertainties, you should not place undue reliance on these forward-looking statements, which speak only as of the date made. All subsequent forward-looking statements attributable to the Company or any person acting on its behalf are expressly qualified in their entirety by this cautionary statement. The Company assumes no obligation to update forward-looking statements or outlook or guidance after the date of this press release whether as a result of new information, future events or otherwise, except as may be required by applicable law.
PharmFilm® and the Aquestive logo are registered trademarks of Aquestive Therapeutics, Inc. All other registered trademarks referenced herein are the property of their respective owners.

Investor Inquiries:
ICR Westwicke
Stephanie Carrington
stephanie.carrington@westwicke.com
646-277-1282

 EX-101.SCH 3 aqst-20231205.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 aqst-20231205_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Security Exchange Name Security Exchange Name Title of 12(b) Security Title of 12(b) Security Written Communications Written Communications Local Phone Number Local Phone Number Trading Symbol Trading Symbol Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, State or Province Entity Address, State or Province Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Document Period End Date Document Period End Date Cover [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Pre-commencement Tender Offer Pre-commencement Tender Offer Soliciting Material Soliciting Material City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Document Type Document Type Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Entity Ex Transition Period Entity Ex Transition Period Entity File Number Entity File Number Entity Address, City or Town Entity Address, City or Town Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Registrant Name Entity Registrant Name EX-101.PRE 5 aqst-20231205_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 6 image_0.jpg begin 644 image_0.jpg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end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Cover
Dec. 05, 2023
Cover [Abstract]  
Document Type 8-K
Document Period End Date Dec. 05, 2023
Entity Registrant Name Aquestive Therapeutics, Inc.
Entity Incorporation, State or Country Code DE
Entity File Number 001-38599
Entity Tax Identification Number 82-3827296
Entity Address, Address Line One 30 Technology Drive
Entity Address, City or Town Warren
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 07059
City Area Code (908)
Local Phone Number 941-1900
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol AQST
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period false
Entity Central Index Key 0001398733
Amendment Flag false
XML 8 aqst-20231205_htm.xml IDEA: XBRL DOCUMENT 0001398733 2023-12-05 2023-12-05 0001398733 false 8-K 2023-12-05 Aquestive Therapeutics, Inc. DE 001-38599 82-3827296 30 Technology Drive Warren NJ 07059 (908) 941-1900 false false false false Common Stock, par value $0.001 per share AQST NASDAQ true false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 23 1 false 0 0 false 0 false false R1.htm 0000001 - Document - Cover Sheet http://aquestive.com/role/Cover Cover Cover 1 false false All Reports Book All Reports aqst-20231205.htm aqst-20231205.xsd aqst-20231205_lab.xml aqst-20231205_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "aqst-20231205.htm": { "nsprefix": "aqst", "nsuri": "http://aquestive.com/20231205", "dts": { "inline": { "local": [ "aqst-20231205.htm" ] }, "schema": { "local": [ "aqst-20231205.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "aqst-20231205_lab.xml" ] }, "presentationLink": { "local": [ "aqst-20231205_pre.xml" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 24, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://aquestive.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "aqst-20231205.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "aqst-20231205.htm", "first": true, "unique": true } } }, "tag": { "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://aquestive.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://aquestive.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://aquestive.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://aquestive.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Written Communications", "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://aquestive.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://aquestive.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://aquestive.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://aquestive.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://aquestive.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://aquestive.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://aquestive.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Issuer Tender Offer", "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://aquestive.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://aquestive.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://aquestive.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://aquestive.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://aquestive.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Ex Transition Period", "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r7" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://aquestive.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://aquestive.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Soliciting Material", "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://aquestive.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Tender Offer", "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://aquestive.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://aquestive.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://aquestive.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://aquestive.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001628280-23-040702-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001628280-23-040702-xbrl.zip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